The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Olakanmi, O.
Right arrow Articles by Britigan, B. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Olakanmi, O.
Right arrow Articles by Britigan, B. E.
The Journal of Immunology, 2002, 169: 2076-2084.
Copyright © 2002 by The American Association of Immunologists

Multivalent Metal-Induced Iron Acquisition from Transferrin and Lactoferrin by Myeloid Cells1

Oyebode Olakanmi*,{ddagger}, George T. Rasmussen*,{ddagger}, Troy S. Lewis*, John B. Stokes*,{ddagger}, John D. Kemp{dagger},§ and Bradley E. Britigan2,*,{ddagger},¶

Departments of * Internal Medicine and {dagger} Pathology, Veterans Affairs Medical Center, Iowa City, IA 52246; and Departments of {ddagger} Internal Medicine and § Pathology, and Free Radical Biology Program, Department of Radiation Oncology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
We previously described a unique, high-capacity, ATP-independent mechanism through which myeloid cells acquire Fe from low-m.w. chelates. The rate of this Fe acquisition is markedly increased by cellular exposure to multivalent metal cations. Because most Fe in vivo is bound to transferrin or lactoferrin, we examined whether this mechanism also contributes to myeloid cell acquisition of Fe from transferrin and/or lactoferrin. Using HL-60 cells as a model system, we show cellular acquisition of 59Fe from both lactoferrin and transferrin that was unaffected by conditions that depleted the cells of ATP or disrupted their cytoskeleton. Fe acquisition was dramatically increased by cell exposure to various metals including Ga3+, Gd3+, Al3+, Fe3+, La3+, Zr4+, Sn4+, Cu2+, and Zn2+ by a process that was reversible. Exposure to these same metals also increased binding of both transferrin and lactoferrin to the cell surface by a process that does not appear to involve the well-described plasma membrane receptor for transferrin. Approximately 60% of the Fe acquired by the cells from transferrin and lactoferrin remained cell associated 18 h later. HL-60 cells possess a high-capacity multivalent metal-inducible mechanism for Fe acquisition from transferrin and lactoferrin that bears many similarities to the process previously described that allows these and other cell types to acquire Fe from low-m.w. Fe chelates. The biologic importance of this mechanism may relate to its high Fe acquisition capacity and the speed with which it is able to rapidly adapt to the level of extracellular Fe.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Iron (Fe) is essential for the growth and metabolism of human cells. However, through its ability to promote the formation of highly reactive oxidant species it is also cytotoxic (1). Presumably for this reason and to limit its availability to pathogenic microorganisms, Fe acquisition, transport, and storage are tightly regulated. In vivo, free extracellular Fe is kept to a minimum (2). The vast majority of extracellular Fe is chelated to one of two related proteins, transferrin and lactoferrin. Transferrin serves as the principal chelator of extracellular Fe in serum, whereas lactoferrin and transferrin both serve this function at mucosal surfaces (3, 4). In addition, extracellular Fe is also bound to a variety of low-m.w. organic chelating agents (4). The amount of these low-m.w. Fe complexes increases in some pathologic states and under conditions of relative Fe overload (5, 6, 7, 8).

Transferrin serves an important role in intercellular transport of Fe. Receptor-mediated endocytosis via a transferrin-specific plasma membrane receptor has been intensely studied and is felt to be the principal mechanism through which most cells acquire Fe from the extracellular environment (9, 10, 11). The transferrin receptor has greater affinity at physiologic pH for diferric transferrin than the apo form of the protein. Transferrin binding is followed by internalization of the receptor-transferrin-Fe complex via endocytosis (9, 10). The Fe is released, in part, by acidification of the endosome and reduction of Fe3+ to Fe2+ (9, 10). The Fe2+ is then transported to the cytoplasm through the action of the divalent metals transporter 1 (DMT-1),3 also known as Nramp2 and DCT-1 (12). The transferrin receptor is then recycled to the plasma membrane, where apotransferrin is released from the receptor (9, 10). The efficiency of Fe acquisition from transferrin is influenced by the association of other proteins, HFE and {beta}2-microglobulin, with the transferrin receptor (13, 14, 15). The absence of functional HFE appears to play a critical role in hereditary hemochromatosis (16).

Other mechanisms may be involved in Fe acquisition from transferrin by some cell types (17, 18, 19, 20, 21, 22, 23, 24). In most studies the mechanism responsible remains ill defined. However, a pathway involving the intracellular protein mobilferrin in conjunction with membrane integrins has been described (21, 22). Melanotransferrin, a plasma membrane-associated Fe-binding protein in human melanoma and other cell lines, has also been implicated in some forms of Fe acquisition from transferrin (23, 24). These processes do not appear to require transferrin internalization. In addition, a second transferrin-specific plasma membrane receptor (transferrin receptor 2) has recently been described in some cell types (25, 26, 27).

The ability of cells to acquire Fe from lactoferrin and the mechanism(s) responsible have been more controversial. Lactoferrin does not bind to the transferrin receptor (28, 29, 30, 31). It does bind to the surface of many cell types, but whether this occurs via a lactoferrin-specific receptor remains unclear (28, 30, 32, 33, 34, 35, 36, 37, 38, 39, 40). Even when lactoferrin binding to cells occurs, resulting Fe acquisition has not been uniformly observed (37, 38, 41, 42).

Many cell types have been shown to acquire Fe bound to a variety of low-m.w. chelating agents in vitro (9, 12, 43, 44, 45, 46, 47). Several mechanisms have been proposed for this acquisition. In some cell types these processes have been linked to stimulator of Fe transport-1 (47) and DMT-1 (12, 48). DMT-1 is particularly important in the ability of intestinal epithelial cells to acquire and transport Fe from the intestinal lumen into the body (12, 49). In studies of the acquisition of Fe from low-m.w. chelates by monocytes, macrophages, neutrophils, and human myeloid cell lines we discovered that these cells possess a unique Fe uptake mechanism that functions even in the presence of marked cellular ATP depletion. Furthermore, the rate of Fe acquisition is markedly increased by prior exposure of the cells to multivalent metal cations, including Fe (44, 50). This process does not appear to require the internalization of the chelating agent. It allows for rapid acquisition of large amounts of Fe by cells, far greater than that usually associated with receptor-mediated endocytosis of Fe from transferrin (44).

Because both transferrin and lactoferrin become associated with the cellular membrane of myeloid cells (28, 32, 33, 34, 35, 36, 37, 51, 52), we hypothesized that the mechanism of Fe acquisition we have described from low-m.w. chelates may also contribute to the ability of myeloid cells to acquire Fe from transferrin or lactoferrin.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Preparation of iron chelates

Ferric nitrilotriacetate (NTA) was prepared by combining equimolar amounts of [59Fe]Cl3 (100 µCi/ml; Amersham, Arlington Heights, IL) and NTA. Diferric transferrin ([59Fe2]transferrin) and diferric lactoferrin ([59Fe2]lactoferrin) were prepared by adding [59Fe]NTA or [59Fe]Cl3 to human apotransferrin or apolactoferrin (Sigma-Aldrich, St. Louis, MO) at a 2:1 molar ratio, in the presence of bicarbonate (53). The mixture was incubated at 4°C overnight after which it was centrifuged and washed three times in a centriprep-30 (Amicon, Beverly, MA) to remove any 59Fe that was not tightly bound to transferrin or lactoferrin.

Cell culture and cell preparation

The human promyelocytic HL-60 cell line was cultured in RPMI 1640 (University of Iowa Cancer Center, Iowa City, IA) supplemented with 10% FCS, glutamine (2 mM; Sigma-Aldrich), penicillin (100 U/ml), and streptomycin (100 µg/ml). Before an experiment, the cells were washed three times in HBSS and resuspended in HBSS at 5 x 106/ml, and 100 µl was placed in the wells of a 96-well plate. The plate was equilibrated in the incubator (5% CO2 at 37°C) for 15 min. Where desired, Ga(NO3)3 was added at a final concentration of 1 mM and incubated for 30 min at 37°C followed by measurements of Fe acquisition over time. In some cases the cells were washed to remove extracellular Ga before measurement of Fe acquisition. All experiments were conducted in duplicate. In each experiment control wells were included which contained cells that had only been exposed to HBSS.

Quantitation of cellular iron acquisition

Cell suspensions were placed at 37°C for 15 min. 59Fe chelate (750 nM) was then added and the cells were incubated for the desired time periods. The cell suspension was then centrifuged at 500 x g for 5 min at 4°C and the medium was carefully removed. The cell pellet in each well was washed three times in the same volume of HBSS and the amount of cell-associated 59Fe was determined by a gamma counter. Parallel experiments were performed each day in the absence of cells to control for possible 59Fe binding to the plate or formation of non-cell-associated Fe aggregates that might have cosedimented with the cells. These values, usually between 0.05 and 0.2% of total cpm added, were subtracted from corresponding experimental samples for each time interval.

We also used a second method to separate cell-associated Fe from free Fe chelates. This method was used to ensure that Fe complexes of transferrin or lactoferrin were not simply cosedimenting nonspecifically with the cells. Aliquots of the cell suspension that had been incubated with Fe were layered on top of an oil cushion (0.5 ml, 4:1 dibutylphthalat:dinonyl) in 1.5-ml conical cryotubes and centrifuged at 10,000 x g for 10 min. The tube was then placed in a dry ice-acetone bath until the liquid solidified. Cell pellets were cut from the bottom of the tubes and the amount of cell-associated 59Fe was determined using a gamma counter. Both methods used to separate cell-associated Fe from extracellular 59Fe yielded similar results.

In some experiments cells were incubated with a combination of metabolic inhibitors, NaCN (1 mM) and 2-deoxy-D-glucose (50 mM), for 2 h at 37°C. After an additional 15 min of incubation at 37°C, Fe acquisition was measured as above.

Measurement of transferrin/lactoferrin binding by HL-60

Apo- or Fe-loaded transferrin or lactoferrin were iodinated using the iodogen method (Pierce, Rockford, IL). Successful iodination of the proteins and the lack of protein degradation following the procedure were confirmed by SDS-PAGE followed by autoradiography. It revealed a single band of radioactivity for each protein migrating at ~80 kDa. More than 80–90% of 125I activity resulting from placement of these iodination proteins in solution could be immunoprecipitated using polyclonal antisera specific to that specific protein (anti-transferrin and anti-lactoferrin).

In preparation for the determination of lactoferrin or transferrin binding, Ga-treated or control cells were washed in HBSS. Cells were equilibrated at 4°C for 10 min and then incubated (2 x 106/ml) with apo- or holo-[125I]transferrin/lactoferrin (563 nM) in a volume of 0.5 ml at 4°C for 15 min, and washed three times. Cell-associated 125I was then assessed by counting the cell pellet in a gamma counter. It has previously been reported that the binding properties of lactoferrin can be altered by iodination procedures (54). However, the iodination procedure used in our work had a negligible effect on binding of either protein to the HL-60 cell surface, as demonstrated by the following results. Binding to HL-60 cells of [59Fe]transferrin and [59Fe]lactoferrin that had been iodinated (using nonradioactive iodine) according to our iodination protocol was compared with noniodinated controls. There was no evidence that the iodination procedure altered binding of either transferrin or lactoferrin to these cells.

Immunoprecipitation of transferrin and lactoferrin

Cells were lysed in TBS containing 1% Triton X-100, 0.1 mg/ml leupeptin and pepstatin A, and 2 mM PMSF (30 min at 4°C). The lysate was incubated with normal rabbit serum for 30 min followed by an additional 30 min in the presence of formalin-fixed protein A-bearing Staphylococcus aureus (Pansorbin cells; Calbiochem, San Diego, CA). The mixture was then centrifuged in a refrigerated microfuge and the supernatant was transferred to a fresh Eppendorf tube. These precleared supernatants were then incubated with polyclonal Ab to human transferrin or lactoferrin (Calbiochem) in 50 mM Tris-Cl and 190 mM NaCl containing 2.5% Triton X-100 for 4 h at 4°C. At that time protein A-Sepharose CL-4B (Amersham Pharmacia Biotech, Piscataway, NJ) was added and the incubation was continued for an additional 60 min. The immune complexes were then pelleted and washed, following which the pellet and supernatant were transferred to a gamma counter for determination of 59Fe or 125I.

FACS analysis

Cells that were pre-exposed to Ga or control cells (without Ga exposure) were incubated with anti-transferrin receptor mAb (A27.15, E2.3) (55, 56), anti-MPO mAb (MPO-7), or normal mouse IgG for nonspecific binding and stained with FITC goat F(ab')2 anti-mouse IgG. Samples were analyzed by FACScan flow cytometer.

Statistical analyses

Results obtained under different experimental conditions were compared by Student’s paired t test when independent variables were being assessed or by ANOVA when analyses of trends were being determined. For both types of analyses results were considered significant at p <= 0.05.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Cationic metals enhance iron acquisition from transferrin and lactoferrin

Previous work from our laboratory indicates that mononuclear and polymorphonuclear phagocytes, as well as human myeloid cell lines such as the promyelocytic HL-60 cell line, can acquire Fe from low-m.w. chelates via a unique mechanism that does not involve receptor-mediated endocytosis (44, 50). This process is not altered by depletion of cellular ATP and the rate and magnitude of Fe acquisition is dramatically increased by cellular exposure to Fe or other polyvalent cationic metals (44, 50). In the present study we examined to what extent this mechanism may also contribute to Fe acquisition from transferrin and lactoferrin by myeloid cells. HL-60 cells were incubated with [59Fe2]transferrin or [59Fe2]lactoferrin for defined time periods, at which time 59Fe associated with the cell was measured. An increase in cell-associated 59Fe was observed over time using either transferrin or lactoferrin (Fig. 1GoA). At each time point, the magnitude of Fe acquired was ~3-fold greater with Fe-lactoferrin relative to Fe-transferrin (Fig. 1GoA).



View larger version (14K):
[in this window]
[in a new window]
  		FIGURE 1. HL-60 iron acquisition from transferrin and lactoferrin is increased by gallium. A, HL-60 cells were suspended in HBSS following which 750 nM [59Fe2]transferrin ({diamond}) or [59Fe2]lactoferrin ({square}) were added. The cell suspension was then incubated for defined time periods at 37°C, after which cell-associated 59Fe was determined. B, Data were obtained under the same conditions except that the HL-60 cells were first incubated with 1 mM Ga(NO3)3 for 30 min before the addition of [59Fe2]transferrin ({diamond}) or [59Fe2]lactoferrin ({square}). The Ga remained throughout the experiment. In both panels cell-associated 59Fe is expressed as pmol of 59Fe acquired/106 cells and the results shown are the mean ± SEM from 9–15 separate experiments.

 
Analogous to its effect on Fe acquisition from low-m.w. chelates (44, 50), Ga(NO3)3 markedly augmented Fe acquisition by HL-60 cells from transferrin and lactoferrin (Fig. 1GoB). The majority of the iron acquired by the cells occurred in the first 10 min (Fig. 1GoB). Other trivalent (Al, Fe, Gd, La) or tetravalent (Sn, Zr) metals had a similar effect (Table IGo). Cell acquisition of Fe from transferrin following incubation with these multivalent ions was increased 5- to 18-fold. The fold stimulation of Fe acquisition from lactoferrin was slightly less: 4- to 7-fold (Table IGo). Two different methods of separating cell-associated from free Fe chelates (see Materials and Methods) produced similar results.


View this table:
[in this window]
[in a new window]
  		Table I. Enhancement of Fe acquisition by various metals1

 
Ga induction of Fe acquisition from either transferrin or lactoferrin was concentration dependent (Fig. 2Go), a result consistent with our previous observations of Fe acquisition from NTA (50). Also similar to previous results with Fe-NTA (44), the divalent metal cations Ca2+, Cd2+, Mg2+, and Mn2+ did not affect acquisition of Fe from either transferrin or lactoferrin (Table IGo). However, in contrast to these earlier data (44), incubation of HL-60 cells with Cu2+ markedly increased Fe acquisition from both transferrin and lactoferrin (Table IGo). Zn2+ also exhibited a modest stimulatory effect (Table IGo).



View larger version (18K):
[in this window]
[in a new window]
  		FIGURE 2. Ga induction of increased Fe uptake is concentration dependent. HL-60 cells were incubated with varying concentrations of Ga(NO3)3 for 30 min at 37°C, then 750 nM [59Fe2]transferrin or [59Fe2]lactoferrin was added. Results are expressed as pmol of 59Fe acquired/106 cells after 60 min of incubation at 37°C (mean ± SEM, n = 3) with [59Fe2]transferrin ({circ}) or [59Fe2]lactoferrin ({square}), as a function of increasing concentrations of Ga.

 
The metals did not have to be continuously present in the extracellular medium during cellular exposure to transferrin or lactoferrin to induce Fe acquisition. Cells that were extensively washed to remove extracellular and loosely associated Ga before measurement of Fe acquisition exhibited a similar rate and magnitude of Fe acquisition from transferrin and lactoferrin as was observed if Ga remained throughout the course of Fe acquisition (Fig. 3Go). Thus, the metals did not increase Fe acquisition by displacing Fe from transferrin or lactoferrin in solution.



View larger version (44K):
[in this window]
[in a new window]
  		FIGURE 3. Ga-induced Fe uptake does not require the continued presence of Ga in solution. HL-60 cells were treated with 1 mM Ga(NO3)3 for 30 min at 37°C. The cells were divided into two groups. One was washed in HBSS to remove extracellular and loosely cell-associated Ga. The second group remained in the presence of Ga(NO3)3. A third group of control cells (untreated) were prepared which were incubated initially in HBSS that did not contain Ga. [59Fe2]Transferrin or [59Fe2]lactoferrin was added to each group of cells and incubated at 37°C for 120 min, following which cell-associated 59Fe was determined. Results are expressed as pmol (mean ± SEM, n = 3) of 59Fe/106 cells following 120 min of incubation with either [59Fe]transferrin or [59Fe]lactoferrin by untreated cells (dotted bars), cells that were washed after 30 min incubation with Ga (filled hatched bars), or cells in which Ga remained (open hatched bars) throughout the time of 59Fe incubation.

 
We then asked whether association of Ga with the plasma membrane is required to maintain the "induced phenotype" for acquisition of Fe from transferrin and lactoferrin. We incubated cells with 1 mM Ga, washed them, and then incubated them with 100 µM NTA for 30 min to chelate and remove membrane-associated Ga (50). When Fe acquisition from [59Fe2]transferrin or [59Fe2]lactoferrin was then measured, cell-associated Fe of the NTA-treated cells was not increased relative to non-Ga-treated control cells. After 120 min Fe acquisition from transferrin was 22.5 ± 4.4 and 19.8 ± 5.4 pmol/106 cells for control and Ga-treated cells, respectively, and 49.7 ± 7.3 and 60.5 ± 5.4 pmol/106 cells from lactoferrin by control and Ga-treated cells, respectively.

Because Fe initially chelated to low-m.w. compounds like NTA stimulates its own acquisition by HL-60 cells (44, 50), we examined the possibility that the difference in the basal rate of Fe acquisition from transferrin compared with lactoferrin (Fig. 1Go) related to differences in the ability of diferric transferrin and diferric lactoferrin to induce the cellular Fe acquisition mechanism. Surprisingly, HL-60 cells incubated with 100 µM Fe-lactoferrin for 30 min exhibited a decreased ability to acquire Fe from NTA relative to control cells (Fig. 4Go). In contrast, an enhancement in Fe acquisition from NTA was observed in cells pretreated with a similar concentration of Fe-transferrin (Fig. 4Go).



View larger version (16K):
[in this window]
[in a new window]
  		FIGURE 4. The amounts of Fe acquired from transferrin/lactoferrin are not related to ability of the chelates to induce an increase in Fe uptake. Cells were preincubated with 100 µM [Fe2]transferrin ({diamond}), [Fe2]lactoferrin ({circ}), or buffer alone ({square}) for 30 min. The cells were washed and then incubated with 750 nM [59Fe]NTA at 37°C. The cells were withdrawn at specified time and cell-associated 59Fe was assessed. Results are mean ± SD of two separate experiments.

 
Ga-induced Fe acquisition from transferrin/lactoferrin does not involve receptor-mediated endocytosis

One characteristic of receptor-mediated uptake is its dependence on metabolic energy levels within the cells. Thus, metabolic inhibitors are used to identify receptor-mediated uptake process. We have previously shown that the combination of NaCN (1 mM) and 2-deoxy-D-glucose (50 mM) reproducibly decreases ATP levels to <2% of control in HL-60 cells (50). This treatment did not alter Fe acquisition from transferrin or lactoferrin by the cells, regardless of whether or not they were treated with Ga before the measurement of Fe uptake. Fe uptake from transferrin and lactoferrin by NaCN/2-deoxy-D-glucose-treated HL-60 cells was 97.9 and 90.3% of untreated cells, respectively (n = 3, p > 0.05, NS). Similarly, Fe acquisition from transferrin and lactoferrin by NaCN/2-deoxy-D-glucose-treated HL-60 cells following a 30-min incubation with Ga was 107.1 and 103.5% of untreated cells, respectively (n = 3, p > 0.05, NS).

The process of receptor-mediated uptake involves the cytoskeleton and results in internalization followed by recycling of the receptor-membrane complex. Cytochalasin B disrupts the cytoskeleton and thus inhibits acquisition of molecules via receptor-mediated endocytosis. When control or Ga-treated HL-60 cells were exposed to cytochalasin B, there was no effect on Fe acquisition from either transferrin or lactoferrin. Fe acquisition from transferrin by cells that had not been exposed to Ga was 3.2 ± 0.8 vs 3 ± 0.8 pmol Fe/106 cells (mean ± SEM, n = 3) in the absence and presence of cytochalasin treatment, respectively. For Ga-treated cells, Fe acquisition from transferrin was 10.9 ± 0.8 pmol Fe/106 without cytochalasin treatment and 10.6 ± 3 pmol Fe/106 cells in its presence (mean ± SEM, n = 3). Fe acquisition from lactoferrin in the absence of Ga pretreatment by control and cytochalasin-treated cells yielded 9.6 ± 0.7 and 12.1 ± 0.5 pmol Fe/106 cells (mean ± SEM, n = 3), respectively. In the case of Fe acquisition from lactoferrin by Ga-treated cells, these values were 50.4 ± 6.3 and 55.6 ± 3.4 pmol Fe/106 cells (mean ± SEM, n = 3) with control and cytochalasin-treated cells, respectively. Thus, disruption of the cytoskeleton has no effect on Ga-stimulated Fe acquisition from transferrin.

Gallium increases binding of transferrin and lactoferrin to HL-60 cells

The classic process of cell acquisition of Fe from transferrin involves the binding of the Fe-transferrin complex to specific receptors on the cell surface. We asked whether the metal-induced increase in Fe acquisition from transferrin and lactoferrin also was associated with the enhanced binding of these Fe-protein complexes to the cell surface.

To test this hypothesis, control or metal-pretreated cells were incubated at 4°C with [125I]diferrictransferrin or [125I]diferriclactoferrin for 15 min. Under these conditions, cell-associated [125I]transferrin or [125I]lactoferrin following Ga, Fe, Gd, La, Al, Sn, or Zr treatment cells was increased 10- to 42-fold over control cells (Table IIGo). The tri- and tetravalent cations increased Fe acquisition and protein binding in roughly similar proportions. However, Cu exposure enhanced Fe acquisition from transferrin 17-fold (Table IGo) but had a much smaller effect on binding of transferrin protein (1.8-fold increase; Table IIGo). The Cu effect on lactoferrin protein and Fe acquisition from lactoferrin was similar (7- to 8-fold increase; Tables IGo and IIGo). Zn, which modestly enhanced Fe acquisition (Table IGo), also increased binding of both proteins only slightly (~4-fold; Table IIGo). No increase in binding of either transferrin or lactoferrin was observed with Cd or Mn (Table IIGo). The magnitude of binding was similar, regardless of whether studies were performed with apo- or iron-loaded transferrin or lactoferrin (Fig. 5Go). In contrast to the results with transferrin and lactoferrin, Ga exposure had a much lesser ability to enhance binding of [125I]-labeled BSA to the cell surface (Fig. 5Go).


View this table:
[in this window]
[in a new window]
  		Table II. Metals vary in their ability to cause increased binding of transferrin or lactoferrin1

 


View larger version (60K):
[in this window]
[in a new window]
  		FIGURE 5. Gallium enhances binding of transferrin and lactoferrin protein to HL-60 cells independent of their iron content. HL-60 cells (5 x 106/ml) were incubated with 1 mM Ga(NO3)3 or buffer only for 30 min at 37°C. The cells were then cooled to 4°C and incubated with [125I]apotransferrin (apo Tf), [125I]diferric transferrin (Fe Tf), [125I]apolactoferrin (apo Lf), [125I]diferric lactoferrin (Fe Lf), [125I]BSA for 15 min at 4°C. Cell-associated 125I was then determined. Data are expressed both as mean ± SEM (n = 3) fold increase over control (no metal induction of HL-60 cells). All increases were statistically significant (p < 0.01).

 
We next asked whether the Ga-induced increase in transferrin and lactoferrin protein association with HL-60 cells was dependent on continued Ga presence on the cell surface. As was the case with Fe acquisition from lactoferrin and transferrin, Ga-mediated enhancement of transferrin/lactoferrin protein binding was reversed when Ga was removed from the cells by chelation with NTA (50). Pretreatment of Ga-incubated cells with NTA reduced both transferrin (apotransferrin and diferric transferrin) and lactoferrin protein binding back to near basal levels (Fig. 6Go). These results suggest that continuous association of Ga with the plasma membrane is required for enhanced transferrin and lactoferrin protein binding. They also suggest that the ability of Ga to increase Fe acquisition is mediated in part through its enhancement of transferrin and lactoferrin binding to the cell surface.



View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 6. Gallium enhancement of binding of transferrin and lactoferrin protein to HL-60 cells is reversed by removal of Ga from the cells. HL-60 cells (5 x 106/ml) were incubated with 1 mM Ga(NO3)3 or buffer only for 30 min at 37°C. Half of each of the two cell groups was incubated with 100 µM NTA for an additional 30 min to chelate and remove membrane-associated Ga. The cells were then cooled to 4°C and incubated with [125I]apotransferrin (apo Tf), [125I]diferric transferrin (Fe Tf), [125I]apolactoferrin (apo Lf), [125I]diferric lactoferrin (Fe Lf), [125I]BSA for 15 min at 4°C. Cell-associated 125I was then determined. Data are expressed both as mean ± SEM (n = 3) fold increase over control (no metal induction of HL-60 cells).

 
Gallium does not increase transferrin receptor density on the plasma membrane

HL-60 cells express transferrin receptors on their plasma membrane. Cycloheximide (1 mM for 60 min) pretreatment had no effect on Ga-mediated enhancement of transferrin or lactoferrin binding to HL-60 cells (data not shown), indicating Ga does not mediate its effects by increasing synthesis of transferrin receptor or any other protein. This is not surprising given that the time of incubation (30 min) required for Ga to produce its augmentation of transferrin and lactoferrin binding should not be sufficient to allow significant increases in protein synthesis.

Another possible explanation for increased transferrin and lactoferrin binding would be if Ga increased the number of transferrin receptors on the cell surface. Cells were exposed to Ga as above and were washed free of non-membrane-associated Ga. Ga-treated and control cells were then incubated with either of two different monoclonal anti-transferrin receptor Abs (A27.15 or E2.3), then stained with FITC-labeled secondary Ab, and surface expression of transferrin receptor was assessed by FACS analysis. There was no statistically significant difference in the level of transferrin receptor 1 on Ga-treated and control cells using monoclonal anti-transferrin receptor Ab (data not shown), indicating that Ga did not increase the number of surface transferrin receptors on HL-60 cells.

Cellular retention of iron, transferrin, and lactoferrin

We next sought to investigate whether the Fe that became cell associated reflected Fe that was taken up in association with the protein or that had been separated from it. Consequently, we compared the amount of protein relative to Fe that became cell associated as a consequence of incubating the cells with diferric transferrin or diferric lactoferrin.

Under basal conditions (Fig. 7GoA), the amount of Fe that became associated with the cells over 1 h at 37°C was ~2-fold greater when it was initially bound to lactoferrin relative to transferrin (Figs. 1GoA and 7A). Cell-associated lactoferrin protein was ~3-fold higher than transferrin (Fig. 7GoA). Ga treatment led to a 10-fold increase in the amount of Fe acquired from transferrin and a 5-fold increase from lactoferrin after 1 h (Fig. 7Go, A vs B). This was mirrored by a similar magnitude of increase in cell-associated transferrin and lactoferrin protein as a consequence of Ga exposure (Fig. 7Go, A vs B) after 1 h of incubation.



View larger version (36K):
[in this window]
[in a new window]
  		FIGURE 7. Relative uptake of [59Fe] and [125I]Tf/Lf by HL-60 cells at 37°C. HL-60 cells that had been treated with HBSS (control) or with 1 mM Ga were incubated with 750 nM [59Fe]transferrin, [59Fe]lactoferrin, [125I]diferric transferrin, or [125I]diferric lactoferrin at 37°C for 2 h. The cells were washed and cell-associated 59Fe and 125I were obtained. Results are expressed in pmol (mean ± SEM, n = 3) 59Fe (open hatched bars) or pmol (mean ± SEM) 125I (filled hatched bars) per 106 cells (n = 3). A, Results after 120 min of incubation with transferrin (Tf) or lactoferrin (Lf) using HL-60 cells not exposed to Ga. B, Results using transferrin or lactoferrin and HL-60 cells preincubated with Ga(NO3)3.

 
There was about twice as much cell-associated Fe compared with transferrin protein with both non-Ga-treated and Ga-treated cells following incubation for 60 min at 37°C (Fig. 8Go). A similar ratio was seen with lactoferrin with non-Ga-treated cells. This approximates the expected molar ratio of fully Fe-loaded lactoferrin or transferrin of two Fe molecules to one protein molecule. With Ga-treated cells this 2:1 ratio was maintained for Fe-loaded transferrin, but for Fe-loaded lactoferrin the ratio fell to ~1:1 (Fig. 8Go). A 2:1 ratio of Fe:transferrin protein association with the cells was also obtained when the incubations were performed at 4°C (Fig. 8Go). Although this was also true with lactoferrin for Ga-treated cells, the ratio of Fe:lactoferrin protein in the absence of Ga treatment was ~5:1 (Fig. 8Go).



View larger version (31K):
[in this window]
[in a new window]
  		FIGURE 8. Relative uptake of [59Fe] and [125I]Tf/Lf by HL-60 cells at 4°C. HL-60 cells that had been treated with HBSS (control) or with 1 mM Ga were incubated with 750 nM [59Fe]transferrin, [59Fe]lactoferrin, [125I]diferric transferrin, or [125I]diferric lactoferrin at 4°C or 37°C for 1 and 2 h, respectively. The cells were washed and cell-associated 59Fe and 125I were obtained. Results are expressed the ratio of cell-associated pmol per 106 cells 59Fe to 125I (n = 3). Open hatched bars represent results of cells under basal conditions, and filled hatched bars represent cells that had been preincubated with Ga(NO3)3.

 
These data are consistent with a process that initially involves binding and retention of Fe as a complex with lactoferrin or transferrin. To examine whether all of the Fe initially associated with the cell remains complexed to lactoferrin or transferrin over the first 2 h of cellular acquisition, HL-60 cells (control or Ga-induced) were incubated in parallel with [59Fe]transferrin, [59Fe]lactoferrin, [125I]transferrin, or [125I]lactoferrin. The cells were washed and lysed, and then cell-associated transferrin or lactoferrin was immunoprecipitated. With this protocol we were able to immunoprecipitate 86–92% of cell-associated protein ([125I]transferrin or [125I]lactoferrin) from both control and Ga-treated cells, but only 57–68% of the 59Fe was recovered by immunoprecipitating transferrin or lactoferrin protein. These results suggest that at least some of the 59Fe was removed from the protein. Cell-free immunoprecipitation experiments using [59Fe]transferrin, [59Fe]lactoferrin, [125I]transferrin, or [125I]lactoferrin revealed similar efficiency (>90%) of capturing 59Fe vs 125I, indicating that these data were not the result of dislodging 59Fe from the protein during the immunoprecipitation procedure.

Both Fe and protein that became cell associated appeared to remain cell associated over a prolonged time period. Control and Ga-treated HL-60 cells were incubated with 59Fe-lactoferrin or 59Fe-transferrin for 2 h, following which the cells were washed and placed back into culture in the absence of 59Fe, lactoferrin, or transferrin. At 18 h the amount of 59Fe retained by the cells was ascertained. As shown in Fig. 9Go, ~60% of Fe initially acquired from transferrin and lactoferrin remained associated with the cell 18 h later. This was true for both control and Ga-induced cells (Fig. 9Go). Similar results were obtained when Fe acquisition from the low-m.w. chelating agent NTA was assessed in a similar manner (Fig. 9Go).



View larger version (40K):
[in this window]
[in a new window]
  		FIGURE 9. Retention of Fe by HL-60 cells. HL-60 cells (4 x 106/ml) were incubated with 1 mM Ga(NO3)3 or HBSS (control) for 30 min followed by incubation with 1 µM [59Fe2]transferrin, [59Fe2]lactoferrin, or [59Fe]NTA for 2 h at 37°C. The cells were centrifuged and the cell pellets were washed three times in HBSS at 4°C. Each group of cells was divided into two groups of triplicate samples. One group was assayed for cell-associated 59Fe by a gamma counter. The other group was resuspended in culture medium at 2 x 106/ml and placed in the incubator at 37°C for 18 h. Cells were centrifuged at 500 x g for 10 min at 4°C. Medium was carefully removed and the amounts of cell-associated and medium-containing 59Fe were measured. Results were expressed as pmol (mean ± SEM, n = 3–5) 59Fe per 106 cells for untreated (filled bars) and Ga-induced cells after 2 h (dotted bars) and then untreated (striped bars) and Ga-induced cells 18 h later (open hatched bars) as a function of the Fe chelate (transferrin, lactoferrin, or NTA) from which they acquired the Fe.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
We have previously provided evidence for the existence of a multivalent metal-inducible high-capacity mechanism for Fe acquisition from low-m.w. chelates by human myeloid cells that functions even under conditions of extremely low ATP availability (44, 50). In the present work, using HL-60 cells as a model system, we now find that a mechanism with many similar features allows for the acquisition of Fe from both transferrin and lactoferrin.

Under basal conditions, cellular Fe acquisition from both lactoferrin and transferrin was demonstrable, with Fe acquisition from lactoferrin somewhat greater than that from transferrin. Exposure of HL-60 cells to a variety of trivalent and tetravalent metals, including Fe, dramatically increased the magnitude of Fe acquisition from both Fe-binding proteins. The majority of the initially cell-associated Fe was still present 18 h later, irrespective of whether the Fe was acquired from transferrin or lactoferrin. Thus, the Fe acquired by this mechanism does not reflect a transient association with the cell surface. Interestingly, nearly all of the increase in Fe acquisition occurred in the first 10 min, which then reached a plateau. This is identical to what we have previously observed with Fe acquisition by myeloid cells from a variety of low-m.w. Fe chelating agents following multivalent metal exposure (44). The reason for these kinetics is unclear. It appears that the interactive sites were almost completely saturated within 30 min in metal-induced cells. The molecular nature of these sites remains to be defined. However, the process does not require endocytosis because it was unaffected by depleting the cells of ATP or disrupting the cytoskeleton.

The ability of Fe and other metals to enhance Fe acquisition from transferrin has been previously reported for some nonmyeloid cell types (17, 18, 19, 20, 57). For example, ferric citrate modestly enhanced Fe acquisition from transferrin by hepatocytes (17), SK-MEL-28 melanoma cells (18, 19, 57), Chinese hamster ovary cells (18), and lens epithelial cells (20). Where examined this process could not be attributed to enhanced transferrin binding to the cell. Gallium enhanced Fe acquisition from transferrin by SK-MEL-28 melanoma cells but was less effective at doing so than Fe (57). To our knowledge the impact of other metals on cellular Fe acquisition from transferrin has not been examined. Minimal data are available regarding the impact of Fe or Ga on Fe acquisition from lactoferrin. Fe reportedly increases uptake of Fe bound to lactoferrin by hepatocytes (58). In contrast, depletion of intracellular Fe increased acquisition of Fe from lactoferrin by a human colon carcinoma cell line (36).

In contrast to results with the trivalent and tetravalent metals, we found that most divalent metals lacked the ability to modulate Fe acquisition from either transferrin or lactoferrin. However, Cu and to a lesser extent Zn increased cellular Fe acquisition from both transferrin and lactoferrin. This was somewhat surprising, as we had previously found that Cu and Zn had no effect when acquisition of Fe bound to low-m.w. chelates was studied (44). This anomalous behavior of Cu and Zn remains unexplained and stands in contrast to an absence of an effect of Cu and Zn on Fe acquisition from transferrin by SK-MEL-28 melanoma cells (57).

How these various metals enhance cellular Fe acquisition also remains unclear. Ga and other metals can bind to the Fe-binding sites of transferrin and lactoferrin (59, 60, 61, 62). Therefore, one explanation could have been displacement of Fe from the binding site(s) on transferrin/lactoferrin by these metals. This would increase the concentration of free extracellular Fe available for acquisition via a transferrin-independent mechanism. If this displacement of Fe occurred in solution, the increased concentration of free Fe might have contributed to the increased Fe acquisition. However, this scenario seems very unlikely because there was no difference in Fe acquisition when extracellular Ga was removed before the measurement of Fe uptake (Fig. 3Go). The effect of Ga (and presumably other metals) must be related to its interaction with the cell.

Fe reduction has been postulated to play a key role in the acquisition of transferrin- and non-transferrin-bound Fe by yeast and some other eukaryotic cells. In addition, Cu regulates Fe uptake from low-m.w. complexes in both yeast and some human cells through its role in enzymes with ferrioxidase activity that contribute to Fe acquisition (45, 63, 64, 65). However, we have previously shown that Fe reductase activity in HL-60 cells is not altered by exposure to Ga and other metals and, thus, the ability of the tri/tetravalent metals to alter cellular Fe acquisition cannot be due to effects on Fe reductase activity (50). Others have in fact reported that monocyte-macrophage ferric reductase activity decreases following exposure to exogenous Fe (66).

Copper, like Fe, is redox active and can serve as a catalyst for the formation of toxic oxidant species such as the hydroxyl radical (67). It has been suggested that formation of such oxidant species may be involved in the ability of these metals to increase Fe acquisition in some cells (18, 20). However, this seems an unlikely explanation for the trivalent metal effects overall, because a number of the metals observed to increase Fe acquisition, e.g., Ga and Gd, are unable to redox cycle or catalyze oxidant production under biologic conditions. We find no evidence for hydroxyl radical formation using spin trapping techniques as a consequence of cellular exposure to 1 mM Ga(NO3)3 (O. Olakanmi, J. B. Stokes, G. T. Rasmussen, and B. E. Britigan, unpublished observation).

Because both transferrin and lactoferrin become associated with the cellular membrane of myeloid cells (28, 32, 33, 34, 35, 36, 37, 51, 52), we hypothesized that the mechanism through which multivalent metals enhance Fe acquisition from transferrin and lactoferrin could be the result of an increase in binding of these proteins to the cell surface. Studies using 125I-labeled transferrin and lactoferrin confirmed that exposure of HL-60 cells to each of the trivalent and tetravalent metals that increased cellular Fe acquisition from lactoferrin and transferrin also dramatically increased binding of these two proteins to the cell surface (Table IIGo). In contrast, the divalent metals that did not increase cellular Fe acquisition also did not enhance protein binding. However, Cu, which increases cell-associated Fe to an extent similar to that seen with the trivalent and tetravalent metals, results in a much smaller increase in lactoferrin or transferrin binding. Thus, with the exception of the effect of Cu, the ability of different metals to enhance Fe acquisition from transferrin and lactoferrin correlates with their ability to enhance the association of these proteins with the cell surface.

For most cell types, extracellular Fe exposure leads to a decrease in transferrin binding through a decrease in surface expression of transferrin receptor (9, 10, 11). Macrophages appear to be an exception to this rule (51). In contrast to our results, Richardson et al. (17) did not find any increase in transferrin binding to hepatocytes as a result of ferric citrate exposure, a process that nevertheless enhanced cellular Fe acquisition from transferrin up to 8-fold. Fe exposure has previously been reported to enhance binding of lactoferrin to rat hepatocytes (58) and the immortalized human respiratory epithelial BEAS-2B cell line (68). In contrast, depletion of intracellular Fe also enhanced lactoferrin binding to the colon carcinoma HT29–18-C1 cell line (36). Whether our data that Ga and other metals enhance cellular binding of transferrin and lactoferrin extend to other cell types requires further study.

Specific receptors for transferrin and lactoferrin have been reported to be present on the surface of myeloid cells (9, 10, 11, 28, 30, 32, 33, 34, 35, 36, 37, 38, 39). The transferrin receptor has been well described (9, 10, 11); however, the identity of cellular lactoferrin receptor(s) remains poorly defined (28, 30, 32, 33, 34, 35, 36, 37, 38, 39). Our data do not suggest that the mechanism responsible for the ability of the various metals to enhance surface binding of these proteins to the cell surface involves an increase in transferrin receptor expression. FACS analysis showed no change in transferrin receptor expression as a function of trivalent metal exposure. Previous work (69) has shown that exposure of HL-60 cells to Ga in the form of Ga-transferrin does lead to an increase in transferrin receptor surface expression. However, this takes several days compared with the brief (<1 h) Ga(NO3)3 exposure used in our studies. Furthermore, transferrin receptor expression in HL-60 cells has been reported to be in the range of 26,000–114,000 sites per cell, depending upon the extent to which the cells have reached confluent growth (69). Thus, the number of transferrin receptors reported to be expressed on the surface of HL-60 cells would be nearly two orders of magnitude less than amount of transferrin binding per cell that we detected after Ga treatment. Because multiple cellular receptors of varying specificity have been reported to exist for lactoferrin (28, 30, 32, 33, 34, 35, 36, 37, 38, 70, 71, 72) it is difficult to definitively approach the cell "receptor" that leads to enhanced lactoferrin binding following cellular exposure to multivalent metals. To our knowledge, extensive studies of the "receptor(s)" whereby lactoferrin binds to HL-60 cells have not been performed.

Despite the similarities between Fe acquisition from transferrin and lactoferrin, there are several differences. The magnitude of binding of lactoferrin protein was severalfold greater than transferrin in both control and metal-treated cells (Fig. 7Go). Copper exposure also had a greater effect on lactoferrin binding to the cell surface relative to transferrin (Table IIGo). Furthermore, in the case of "uninduced" HL-60 cells, Fe acquisition from lactoferrin was ~3-fold greater than that from transferrin in normal (uninduced) cells (Fig. 1GoA). After Ga induction the difference was much less dramatic. Finally, Fe-transferrin was able to induce Fe acquisition from Fe-NTA, whereas Fe-lactoferrin could not and Fe-lactoferrin actually inhibited the normal Fe-NTA induction (Fig. 4Go). Although these proteins are closely related, there are physicochemical features that are different between the two proteins that could impact on their binding properties and their interaction with cellular membranes. Such differences include their isoelectric points (~9 for lactoferrin and 5–5.5 for transferrin) (73) and differences in glycosylation (10, 74).

Regardless of whether the cells were studied in the basal state or after Ga exposure, the amount of Fe that initially became cell associated was close to the 2:1 molar binding ratio of Fe:transferrin and Fe:lactoferrin. These data are consistent with a process that initially involves binding and retention of Fe as a complex with lactoferrin or transferrin. DMT-1 is expressed in most cell types (75), including macrophages (76, 77, 78, 79), making it a candidate for involvement in the eventual removal of Fe from transferrin or lactoferrin in the system we have described. DMT-1 is expressed on the surface of intestinal epithelial cells (80). Although DMT-1 has been detected in macrophage early endosomes (79), it is not known whether it is similarly localized on the plasma membrane of myeloid cells. However, the events that lead to the subsequent internalization, storage, or secretion of Fe and/or transferrin and lactoferrin by these cells over time require further delineation.

In summary, HL-60 cells possess a high-capacity multivalent metal-inducible mechanism for Fe acquisition from transferrin and lactoferrin that bears many similarities to the process previously described (44), which allows these and other cells types to acquire Fe from low-m.w. Fe chelates. This acquisition is not via the classic transferrin receptor pathway. The potential biologic importance of this mechanism may relate to its high Fe acquisition capacity, with which it is able to rapidly respond to an increased level of extracellular Fe. In a condition of acute Fe overload in which rapid Fe sequestration may be desirable, cells that function in Fe storage, such as macrophages, would benefit from a mechanism with rapid activation and high capacity. Evidence presented here suggests a role for increased surface binding of transferrin and lactoferrin to the cell surface in the ability of metals to enhance Fe acquisition from these proteins. Further work is required to delineate the mechanism and cellular consequences of Fe acquired from these two key Fe-binding proteins via this process as well as the extent to which it is present in other cell types.


   Footnotes
 
1 This work was supported in part by grants from the Research Service of the Department of Veterans Affairs (to B.E.B. and J.B.S.) and U.S. Public Health Service Grants RO1AI43954 and RO3AI43870. Back

2 Address correspondence and reprint requests to Dr. Bradley E. Britigan, Department of Internal Medicine, University of Iowa Hospitals and Clinics, SW54, GH, Iowa City, IA 52242. E-mail address: bradley-britigan{at}uiowa.edu Back

3 Abbreviations used in this paper: DMT-1, divalent metals transporter 1; NTA, nitrilotriacetate. Back

Received for publication April 12, 2002. Accepted for publication June 12, 2002.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Miller, R. A., B. E. Britigan. 1995. The formation and biologic significance of phagocyte-derived oxidants. J. Invest. Med. 43:39.[Medline]
  2. Bullen, J. J., H. J. Rogers, E. Griffiths. 1978. Role of iron in bacterial infection. Curr. Top. Microbiol. Immunol. 80:1.[Medline]
  3. Finkelstein, R. A., C. V. Sciortino, M. A. McIntosh. 1983. Role of iron in microbe-host interactions. Rev. Infect. Dis. 5:5759.
  4. Halliwell, B., J. M. C. Gutteridge. Free Radicals in Biology and Medicine 346. Clarendon, Oxford.
  5. Halliwell, B., O. I. Aruoma, G. Mufti, A. Bomford. 1988. Bleomycin-detectable iron in serum from leukaemic patients before and after chemotherapy: therapeutic implications for treatment with oxidant-generating drugs. FEBS Lett. 241:202.[Medline]
  6. Halliwell, B., J. M. C. Gutteridge. 1990. Role of free radicals and catalytic metals in human disease: an overview. Methods Enzymol. 186:1.[Medline]
  7. Buettner, G. R., W. Chamulitrat. 1990. The catalytic activity of iron in synovial fluid as monitored by the ascorbate free radical. Free Radical Biol. Med. 8:55.[Medline]
  8. Thompson, A. B., T. Bohling, A. Heires, J. Linder, S. I. Rennard. 1991. Lower respiratory tract iron burden is increased in association with cigarette smoking. J. Lab. Clin. Med. 117:493.[Medline]
  9. Ponka, P.. 1999. Cellular iron metabolism. Kidney Int. 55:S2.
  10. De Jong, G., J. P. Van Dijk, H. G. Van Eijk. 1990. The biology of transferrin. Clin. Chim. Acta 190:1.[Medline]
  11. Thorstensen, K., I. Romslo. 1990. The role of transferrin in the mechanism of cellular iron uptake. Biochem. J. 271:1.[Medline]
  12. Gunshin, H., B. Mackenzie, U. V. Berger, Y. Gunshin, M. F. Romero, W. F. Boron, S. Nussberger, J. L. Gollan, M. A. Hediger. 1997. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388:482.[Medline]
  13. Lebrón, J. A., M. J. Bennet, D. E. Vaughn, A. J. Chirino, P. M. Snow, G. A. Mintier, J. N. Feder, P. J. Bjorkman. 1998. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 93:111.[Medline]
  14. Waheed, A., J. H. Grubb, X. Y. Zhou, S. Tomatsu, R. E. Fleming, M. E. Costaldi, R. S. Britton, B. R. Bacon, W. S. Sly. 2002. Regulation of transferrin-mediated iron uptake by HFE, the protein defective in hereditary hemochromatosis. Proc. Natl. Acad. Sci. USA 99:3117.[Abstract/Free Full Text]
  15. Roy, C. N., D. M. Penny, J. N. Feder, C. A. Enns. 1999. The hereditary hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells. J. Biol. Chem. 274:9022.[Abstract/Free Full Text]
  16. Cuthbert, J. A.. 1997. Iron, HFE, and hemochromatosis update. J. Invest. Med. 45:518.[Medline]
  17. Richardson, D. R., A. C. G. Chua, E. Baker. 1999. Activation of an iron uptake mechanism from transferrin in hepatocytes by small-molecular-weight iron complexes: implications for the pathogenesis of iron-overload disease. J. Lab. Clin. Med. 133:144.[Medline]
  18. Richardson, D. R., P. Ponka. 1995. Identification of a mechanism of iron uptake by cells which is stimulated by hydroxyl radicals generated via the iron-catalysed Haber-Weiss reaction. Biochim. Biophys. Acta 1269:105.[Medline]
  19. Richardson, D. R., E. Baker. 1992. The effect of desferrioxamine and ferric ammonium citrate on the uptake of iron by the membrane iron-binding component of human melanoma cells. Biochim. Biophys. Acta 1103:275.[Medline]
  20. Goralska, M., J. Harned, L. N. Fleisher, M. C. McGahan. 1998. The effect of ascorbic acid and ferric ammonium citrate on iron uptake and storage in lens epithelial cells. Exp. Eye Res. 66:687.[Medline]
  21. Conrad, M. E., J. N. Umbreit, E. G. Moore, C. Uzel, M. R. Berry. 1994. Alternate iron transport pathway: mobilferrin and integrin in K562 cells. J. Biol. Chem. 269:7169.[Abstract/Free Full Text]
  22. Conrad, M. E., J. N. Umbreit, E. G. Moore, D. Heiman. 1996. Mobilferrin is an intermediate in iron transport between transferrin and hemoglobin in K562 cells. J. Clin. Invest. 98:1449.[Medline]
  23. Kennard, M. L., D. R. Richardson, R. Gabathuler, P. Ponka, W. A. Jefferies. 1995. A novel iron uptake mechanism mediated by GPI-anchored human p97. EMBO J. 14:4178.[Medline]
  24. Richardson, D. R., E. Baker. 1992. Intermediate steps in cellular iron uptake from transferrin: detection of a cytoplasmic pool of iron, free of transferrin. J. Biol. Chem. 267:21384.[Abstract/Free Full Text]
  25. Kawabata, H., S. Yang, T. Hirama, P. T. Vuong, S. Kawano, A. F. Gombart, H. P. Koeffler. 1999. Molecular cloning of transferrin receptor 2: a new member of the transferrin receptor-like family. J. Biol. Chem. 274:20826.[Abstract/Free Full Text]
  26. Fleming, R. E., M. C. Migas, C. C. Holden, A. Waheed, R. S. Britton, S. Tomatsu, B. R. Bacon, W. S. Sly. 2000. Transferrin receptor 2: continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis. Proc. Natl. Acad. Sci. USA 97:2214.[Abstract/Free Full Text]
  27. Kawabata, H., R. S. Germain, P. T. Vuong, T. Nakamaki, J. W. Said, H. P. Koeffler. 2000. Transferrin receptor 2-{alpha} supports cell growth both in iron-chelated cultured cells and in vivo. J. Biol. Chem. 275:16618.[Abstract/Free Full Text]
  28. Britigan, B. E., J. S. Serody, M. B. Hayek, L. M. Charniga, M. S. Cohen. 1991. Uptake of lactoferrin by mononuclear phagocytes inhibits their ability to form hydroxyl radical and protects them from membrane autoperoxidation. J. Immunol. 147:4271.[Abstract]
  29. Hu, W.-L., J. Mazurier, G. Sawatzki, J. Montreuil, J. Spik. 1988. Lactotransferrin receptor of mouse small-intestinal brush border: binding characteristics of membrane-bound Triton X-100-solubilized forms. Biochem. J. 249:435.[Medline]
  30. Davidson, L. A., B. Lonnerdal. 1988. Specific binding of lactoferrin to brush-border membrane: ontogeny and effect of glycan chain. Am. J. Physiol. 254:G580.[Abstract/Free Full Text]
  31. Birgens, H. S., N. E. Hansen, H. Karle, L. O. Kristensen. 1983. Receptor binding of lactoferrin to human monocytes. Br. J. Haematol. 54:383.[Medline]
  32. Miyazawa, K., C. Mantel, L. Lu, D. C. Morrison, H. E. Broxmeyer. 1991. Lactoferrin-lipopolysaccharide interactions: effect on lactoferrin binding to monocyte/macrophage-differentiated HL-60 cells. J. Immunol. 146:723.[Abstract]
  33. Bennatt, D. J., Y. Y. Ling, D. D. McAbee. 1997. Isolated rat hepatocytes bind lactoferrins by the RHL-1 subunit of the asialoglycoprotein receptor in a galactose-independent manner. Biochemistry 36:8367.[Medline]
  34. Mazurier, J., D. Legrand, W. L. Hu, J. Montreuil, G. Spik. 1989. Expression of human lactotransferrin receptors in phytohemagglutinin-stimulated human peripheral blood lymphocytes: isolation of the receptors by antiligand-affinity chromatography. Eur. J. Biochem. 179:481.[Medline]
  35. Bennett, R. M., J. Davis. 1981. Lactoferrin binding to human peripheral blood cells: interaction with a B-enriched population of lymphocytes and a subpopulation of adherent mononuclear cells. J. Immunol. 127:1211.[Medline]
  36. Mikogami, T., T. Marianne, G. Spik. 1995. Effect of intracellular iron depletion by picolinic acid on expression of the lactoferrin receptor in the human colon carcinoma cell subclone HT29–18-C1. Biochem. J. 308:391.
  37. Ismail, M., J. H. Brock. 1993. Binding of lactoferrin and transferrin to the human promonocytic cell line U937: effect on iron uptake and release. J. Biol. Chem. 268:21618.[Abstract/Free Full Text]
  38. McAbee, D. D.. 1995. Isolated rat hepatocytes acquire iron from lactoferrin by endocytosis. Biochem. J. 311:603.
  39. Fillebeen, C., L. Descamps, M. P. Dehouck, L. Fenart, M. Benaïssa, G. Spik, R. Cecchelli, A. Pierce. 1999. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J. Biol. Chem. 274:7011.[Abstract/Free Full Text]
  40. Damiens, E., I. El Yazidi, J. Mazurier, E. Elass-Rochard, I. Duthille, G. Spik, Y. Boilly-Marer. 1998. Role of heparan sulphate proteoglycans in the regulation of human lactoferrin binding and activity in the MDA-MB-231 breast cancer cell line. Eur. J. Cell Biol. 77:344.[Medline]
  41. Birgens, H. S., L. O. Kristensen, N. Borregaard, H. Karle, N. E. Hansen. 1988. Lactoferrin-mediated transfer of iron to intracellular ferritin in human monocytes. Eur. J. Haematol. 41:52.[Medline]
  42. Oria, R., X. Alvarez-Hernandez, J. Liceaga, J. H. Brock. 1988. Uptake and handling of iron from transferrin, lactoferrin and immune complexes by a macrophage cell line. Biochem. J. 252:221.[Medline]
  43. Kaplan, J., I. Jordan, A. Sturrock. 1991. Regulation of the transferrin-independent iron transport system in cultured cells. J. Biol. Chem. 266:2997.[Abstract/Free Full Text]
  44. Olakanmi, O., J. B. Stokes, B. E. Britigan. 1994. Acquisition of iron bound to low molecular weight chelates by human monocyte-derived macrophages. J. Immunol. 153:2691.[Abstract]
  45. Attieh, Z. K., C. K. Mukhopadhyay, V. Seshadri, N. A. Tripoulasi, P. L. Fox. 1999. Ceruloplasmin ferroxidase activity stimulates cellular uptake by a trivalent cation-specific transport mechanism. J. Biol. Chem. 274:1116.[Abstract/Free Full Text]
  46. De Silva, D. M., C. C. Askwith, J. Kaplan. 1996. Molecular mechanisms of iron uptake in eukaryotes. Physiol. Rev. 76:31.[Abstract/Free Full Text]
  47. Gutierrez, J. A., J. Yu, S. Rivera, M. Wessling-Resnick. 1997. Functional expression cloning and characterization of SFT, a stimulator of Fe transport. J. Cell Biol. 139:895.[Abstract/Free Full Text]
  48. Fleming, M. D., M. A. Romano, M. A. Su, L. M. Garrick, M. D. Garrick, N. C. Andrews. 1998. Nramp2 is mutated in the anemic Belgrade (b) rate: evidence of a role for Nramp2 in endosomal iron transport. Proc. Natl. Acad. Sci. USA 95:1148.[Abstract/Free Full Text]
  49. Fleming, M. D., I. C. C. Trenor, M. A. Su, D. Foernzler, D. R. Beier, W. F. Dietrich, N. C. Andrews. 1997. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat. Genet. 16:383.[Medline]
  50. Olakanmi, O., J. B. Stokes, S. Pathan, B. E. Britigan. 1997. Polyvalent cationic metals induce the rate of transferrin-independent iron acquisition by HL-60 cells. J. Biol. Chem. 272:2599.[Abstract/Free Full Text]
  51. Testa, U., M. Petrini, M. T. Quaranta, E. Pelosi-Testa, G. Mastroberardino, A. Camagna, G. Boccoli, M. Sargiacomo, G. Isacchi, A. Cozzi, et al 1989. Iron up-modulates the expression of transferrin receptors during monocyte-macrophage maturation. J. Biol. Chem. 264:13181.[Abstract/Free Full Text]
  52. Kemp, J. D.. 1993. The role of iron and iron binding proteins in lymphocyte physiology and pathology. J. Clin. Immunol. 13:81.[Medline]
  53. Edeker, B. L., G. T. Rasmussen, B. E. Britigan. 1995. Bicarbonate and phosphate ions protect transferrin from myeloperoxidase-mediated damage. J. Leukocyte Biol. 58:59.[Abstract]
  54. Rosenmund, A., C. Kuyas, A. Haeberli. 1986. Oxidative radioiodination damage to human lactoferrin. Biochem. J. 240:239.[Medline]
  55. Kovar, J., P. W. Neumann, B. C. Stewart, J. D. Kemp. 1995. Differing sensitivity of non-hematopoietic human tumors to synergistic anti-transferrin receptor monoclonal antibodies and deferoxamine in vitro. Pathobiology 63:65.[Medline]
  56. White, S., R. Taetle, P. A. Seligman, M. Rutherford, I. S. Trowbridge. 1990. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. Cancer Res. 50:6295.[Abstract/Free Full Text]
  57. Richardson, D. R.. 2001. Iron and gallium increase iron uptake from transferrin by human melanoma cells: further examination of the ferric ammonium citrate-activated iron uptake process. Biochim. Biophys. Acta 1536:43</